Session Information

  • WCLC 2020

    2020 World Conference on Lung Cancer

    Conference Program for the 2020 World Conference on Lung Cancer in Singapore


    Presentation Date(s):  
    • January 28 - 31, 2021
    • Total Presentations: 1597

    All times listed are in Singapore time (GMT+8)

    PL - Plenary
    PS - Presidential Symposium
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    FP - Featured Posters
    P - Posters
    IS - Industry Symposium
    JICC - Joint IASLC-CAALC-CSCO Session

Filter Results:

Show Only CME Accredited Sessions

  • +

    P09 - Health Services Research/Health Economics - Real World Outcomes

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Health Services Research/Health Economics
    • +

      P09.13 - Bone Metastases and Overall Survival in Patients with Metastatic Non-Small Cell Lung Cancer Treated with Pembrolizumab

      00:00 - 00:00  |  Presenter: Parthib Das

      • Abstract

      Loading...

  • +

    P21 - Locoregional and Oligometastatic Disease - Treatment of Locally Advanced NSCLC

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Locoregional and Oligometastatic Disease
    • +

      P21.02 - Incidence and Outcomes of Brain Metastases in Unresectable Stage III Patients with NSCLC Treated with Durvalumab after Chemoradiation

      00:00 - 00:00  |  Presenter: Sandip H Patel

      • Abstract

      Loading...

  • +

    P48 - Small Cell Lung Cancer/NET - Chemo - IO

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Small Cell Lung Cancer/NET
    • +

      P48.19 - Outcomes of Patients Treated with First Line Immunotherapy Plus Chemotherapy for ES-SCLC: Real World Outcomes from a Tertiary Academic Center

      00:00 - 00:00  |  Presenter: Sandip H Patel

      • Abstract

      Loading...

  • +

    P75 - Immunotherapy (Phase II/III Trials) - Misc. Topics

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Immunotherapy (Phase II/III Trials)
    • +

      P75.12 - Prognostic Value of Neutrophil to Lymphocyte Ratio in NSCLC Patients Receiving First Line Immune Checkpoint Inhibitor Therapy

      00:00 - 00:00  |  Presenter: Nitya Surya

      • Abstract

      Loading...

  • +

    P78 - Immunotherapy (Phase II/III Trials) - Immune Checkpoint Inhibitor Single Agent

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Immunotherapy (Phase II/III Trials)
    • +

      P78.05 - Patterns of irAE During First Line Pembrolizumab for NSCLC: Incidence, Risk Factors, and Impact on Clinical Outcome

      00:00 - 00:00  |  Presenter: Cameron Champion Wood

      • Abstract

      Loading...

  • +

    P79 - Immunotherapy (Phase II/III Trials) - Immunotherapy Plus Chemotherapy

    • 00:00 - 00:00
    • 1/28/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Immunotherapy (Phase II/III Trials)
    • +

      P79.04 - A Phase 2 Trial of Nivolumab and Temozolomide in Extensive Stage Small Cell Lung Cancer: Interim Efficacy Analysis.

      00:00 - 00:00  |  Presenter: Dwight H Owen

      • Abstract

      Loading...